belzutifan
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
belzutifan
May 23, 2024, 13:10 |
Societies
Updated ESMO Clinical Practice Guideline on Renal Cell Carcinoma - ESMO
ESMO – European Society for Medical Oncology posted on LinkedIn: “Updated Renal Cell Carcinoma: ESMO…
May 23, 2024, 07:58 |
Insight
Tom Powles on new ESMO guidelines for renal cancer
Tom Powles, Director of Barts Cancer Center, shared on X: "New ESMO guidelines in advanced papillary…
Feb 2, 2024, 17:33 |
Drugs
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted: "Day 3 of GU24 ASCO Highlights 1. KN564: Adj Pembro w/…
Dec 24, 2023, 18:54 |
Drugs
Laurie Glimcher: Belzutifan is approved by the FDA
Laurie Glimcher, President and CEO of Dana-Farber Cancer Institute, shared on X/Twitter: "Exciting news that…
Dec 18, 2023, 21:06 |
Insight
Toni Choueiri: A new option for our Kidney Cancer patients!
Toni Choueiri shared on LinkedIn: "JUST IN: FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell…
All:
5
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube